Expertise in
9
conditions

Pascal Chanez

Marseille, FR 
Expertise in
9
conditions
Marseille, FR 

Overview

Pascal Chanez practices practicing medicine in Marseille, France.

Mr. Chanez is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Eosinophilic Asthma, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Endoscopy, and Lung Transplant.

He is actively involved in clinical research, co-authoring 223 peer reviewed articles and participating in 11 clinical trials.

Gender

Male

Locations

Marseille, France
Other Locations
Toulouse, 31059, France
Aix-en-provence, France
CHRU Tours
Tours, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Computed Tomography Air-trapping Characterisation for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients
Computed Tomography Air-trapping Characterisation for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients
Enrollment Status: Completed
Publish Date: June 15, 2026
Intervention Type: Other, Drug
Study Phase: Not Applicable
Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation: a Double-blind, Randomized, Controlled Trial
Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation: a Double-blind, Randomized, Controlled Trial
Enrollment Status: Terminated
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drug: 5 days of Systemic Corticotherapy (Prednisone)
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
Circulating Tumor Cells and Early Diagnosis of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease
Circulating Tumor Cells and Early Diagnosis of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: March 24, 2026
Intervention Type: Biological
Study Phase: Not Applicable
Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi
Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi
Enrollment Status: Completed
Publish Date: November 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
EFFECT OF SMOKING ON MUCUS HYPERSECRETION MECHANISMS IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
EFFECT OF SMOKING ON MUCUS HYPERSECRETION MECHANISMS IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Double Blind (Sponsor Open) Placebo-controlled, Stratified, Parallel Group Study to Evaluate the Efficacy and Safety of Repeat Doses of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
A Double Blind (Sponsor Open) Placebo-controlled, Stratified, Parallel Group Study to Evaluate the Efficacy and Safety of Repeat Doses of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
Enrollment Status: Terminated
Publish Date: October 23, 2020
Intervention Type: Drug
Study Phase: Phase 2
How Participants Perceive Biomedical Research in Pulmonology
How Participants Perceive Biomedical Research in Pulmonology
Enrollment Status: Completed
Publish Date: March 10, 2020
Intervention Type: Other
View 9 Less Clinical Trials

223 Total Publications

Impact of Pollen Exposure on Health and Exercise Performance: A Scoping Review.
Impact of Pollen Exposure on Health and Exercise Performance: A Scoping Review.
Journal: International journal of sports medicine
Published: July 30, 2026

Frequently Asked Questions about Pascal Chanez

Is Pascal Chanez a top-rated expert for Eosinophilic Asthma?

MediFind is an objective health platform that identifies experts based on real-world data. Pascal Chanez is classified as an Elite expert for Eosinophilic Asthma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Pascal Chanez participate in research or clinical trials?

Yes. Pascal Chanez has published 223 articles and abstracts on conditions like Eosinophilic Asthma. You can view a list of Pascal Chanez's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Chanez's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile